A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors

Inclusion Criteria: * 1\. Fully understand the clinical study and voluntarily sign the written ICF; * 2\. Age ≥ 18 years; * 3\. Have at least one measurable lesion according to RECIST 1.1; * 4\. ECOG performance status score of 0 to 1; * 5\. Have adequate organ function; * 6\. Expected survival of at least 3 months; * 7\. Eligible participants of childbearing potential must agree to use a reliable method of contraception with their partner during the study and for at least 6 months after the last dose. Female participants of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose; * 8\. Histologically or cytologically confirmed diagnosis of advanced solid tumors. Exclusion Criteria: * 1\. Patients with other active malignant tumors; * 2\. Uncontrolled serous effusions requiring frequent drainage or medical intervention within 14 days prior to the first dose; * 3\. Serious chronic or active infection; * 4\. Surgical on vital organs within 4 weeks prior to the first dose or planned systemic or local tumor resection during the study; * 5\. Untreated (including baseline findings) or unstable parenchymal metastases, spinal cord metastases or compression, carcinomatous meningitis; * 6\. History of non-infectious lung disease/pneumonitis requiring steroid hormone therapy or current interstitial lung disease/pneumonitis or suspected by imaging during screening; * 7\. History of significant cardiovascular disease; * 8\. History of immunodeficiency, Active hepatitis B or hepatitis C; * 9\. Known serious allergic reactions to the study drug or other ingredients and excipients in the formulation; * 10\. Pregnant or lactating women; * 11\. Presence of other conditions that could interfere with the participant 's participation in study procedures or would not be in the best interest of the participant' s participation in the study or affect the study results: such as a history of mental illness, drug use, or drug abuse, any other clinically significant disease or condition.